logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure EYE-1. Cannabis prevalence rates [see all figures in this series...]

Part (xii) Comparision of trends in average (weighted) lifetime prevalence of cannabis (%) among 15-16 year old school students in Europe, USA and Australia


The EU average is made up of 19 countries that have all 4 survey points and it is weighted by population size. The countries included are Cyprus, Norway, Sweden, Finland, Malta, Portugal, Hungary, Poland, Lithuania, Croatia, Denmark, Ireland, Slovenia, Italy, Estonia, United Kingdom, Slovakia, Spain, Czech Republic, (listed in order of prevalence from lowest to highest). The average reported by ESPAD is unweighted and therefore slightly different.

Although Spain did not participate in the ESPAD survey it is included because drug prevalence questions are comparable to the ESPAD questions. Other aspects of the method mean that Spanish data is not strictly comparable. Belgium data for 2007 is based on Flanders only and German data is based on seven regions only (Bavaria, Brandenburg, Berlin, Hesse, Mecklenburg-Western Pomerania, Saarland and Thuringia). ESPAD 2007 data for Denmark limited comparability.

* In Australian survey the age range is 16-17, prevalence is therefore expected to be higher than for 15-16 year olds. Surveys conducted in 1996, 1999, 2002 and 2005


Hibell et al, ESPAD surveys 1995, 1999, 2003, 2007

(see the help page for information about formats etc.)

Page last updated: Friday, 09 July 2010